"AI would take on the bureaucratic, operational, and repetitive work, allowing humans to focus their time on creativity, scientific reasoning, and critical thinking.” Charlotte Barker (Editor, Vaccine Insights) speaks with Demetris N Zambas (Global Head, Clinical Data and Information Sciences, Clinical Development and Operations, Pfizer R&D) and Lynne Cesario (Executive Director, Risk-Based Monitoring Program Lead and AI Program Lead, Pfizer) about the role of AI in risk-based management of clinical trials, and their approach to integrating these new tools into established teams and processes.
Zambas et al. (Wed,) studied this question.